Abstract 89P
Background
Immune checkpoint inhibitors (ICIs) have drastically shifted the current landscape for a wide variety of malignancies. However, ICIs are interrupted due to immune-related adverse events (irAEs), therapy completion or disease progression. The risk-benefit of rechallenged ICIs remains inconclusive. Herein, a systematic review and meta-analysis were conducted to evaluate the safety and efficacy of ICIs rechallenge in advanced solid tumor.
Methods
PubMed, Web of Science, Embase and Cochrane library were searched for analyzing the efficacy and safety of ICIs rechallenge. We prospectively registered the protocol in PROSPERO International Register of Systematic Reviews (CRD42022372222). The last update search date was March 2nd, 2024. Objective response rates (ORR), disease control rates (DCR), overall survival (OS) and the incidence rates of all-grade and high-grade irAEs were evaluated.
Results
A total of 41 retrospective studies comprising 2343 patients were ultimately enrolled for qualitative and quantitative assessment. 1200 (51.2%) individuals were male and the median age was 66 years, ranged from 18 to 97 years. The majority of tumor types were lung cancer (n=898, 38.3%). The occurrence rates of all-grade and high-grade (grade 3 or 4) irAEs between ICIs initial and readministration were not different significantly (all-grade: OR, 0.75, 95% CI: 0.39–1.45, p=0.40; I2 =87%; high-grade: OR, 0.96, 95% CI: 0.62–1.49, p=0.87, I2 =65%). ICIs restart presented a decreased ORR and DCR compared to initial ICIs administration (ORR: OR, 0.36, 95% CI: 0.23–0.56, p<0.00001; I2 =67%; DCR: OR, 0.62, 95% CI: 0.43–0.89, p=0.010; I2 =53%). Seven studies with 513 patients for survival analysis revealed a non-significantly different OS between ICIs rechallenge and discontinuation cohorts (HR: 0.68, 95% confidence interval (CI): 0.35 to 1.35, p=0.27).
Conclusions
It is feasible to rechallenge immunotherapy, while patients should be carefully evaluated by a multidisciplinary team for close monitoring and assessment of the risk-benefit ratio, prior to initial therapy. It is greatly essential to perform prospective trials to guide clinicians to make decisions.
Legal entity responsible for the study
The author.
Funding
Health Commission of Anhui Province Scientific Research Project (NO.AHWJ2023BAc10031 and AHWJ2023A30183).
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
146P - Neoadjuvant adebrelimab combined with chemotherapy for adenocarcinoma of esophagogastric junction: A single-arm, single-center, phase II clinical trial
Presenter: Jinqiang Liu
Session: Poster Display session
Resources:
Abstract
147P - Serplulimab combined with chemotherapy in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: A single-arm phase II trial
Presenter: Zixiang Wu
Session: Poster Display session
Resources:
Abstract
148P - Neoadjuvant camrelizumab plus metronomic chemotherapy in patients with advanced esophageal squamous cell carcinomas: A randomized phase II trial
Presenter: JIE LIU
Session: Poster Display session
Resources:
Abstract
149P - Toripalimab and chemotherapy as first line combination in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: Kai Zhu
Session: Poster Display session
Resources:
Abstract
150P - Interim results of the multicenter phase II study on induction pembrolizumab plus chemotherapy followed by radiotherapy in locally advanced head and neck cancer
Presenter: Tatiana Antonova
Session: Poster Display session
Resources:
Abstract
151P - Anti-tumor T cell response and immunoselection under combined GARP:TGF-?1/PD-1 blockade
Presenter: Grégoire de Streel
Session: Poster Display session
Resources:
Abstract
152P - TACTI-003 Cohort B: Eftilagimod alpha (Soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head & neck squamous cell carcinoma with PD-L1 negative
Presenter: Martin Forster
Session: Poster Display session
Resources:
Abstract
153P - Combination of Tim-3 blockade TQB2618 with PD-1 blockade for patients with immunotherapy-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Preliminary results from a phase II study
Presenter: Cheng Xu
Session: Poster Display session
Resources:
Abstract
154P - Casdozokitug (casdozo, CHS-388), a first-in-class IL-27 antagonistic antibody, as monotherapy in treatment-refractory non-small cell lung cancer (NSCLC)
Presenter: Aung Naing
Session: Poster Display session
Resources:
Abstract
155P - Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1
Presenter: Anne Chiang
Session: Poster Display session
Resources:
Abstract